FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
The U.S. Food and Drug Administration has approved the first oral PCSK9 inhibitor, a new type of cholesterol-lowering medication for adults with high cholesterol. This marks a significant development in cardiovascular treatment, as previous PCSK9 inhibitors were only available as injectable drugs. The newly approved pill targets the PCSK9 protein, which plays a role in regulating LDL, commonly known as bad cholesterol. The approval offers patients a more convenient oral alternative to manage elevated LDL levels and reduce cardiovascular risk.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in